Sorrento Therapeutics, Inc.
Case Number:
4:23-bk-90085
Court:
Nature of Suit:
Firms
- Gibbs Giden
- Martin P. Eramo APC
- Duane Morris
- Greenberg Traurig
- Norton Rose
- DLA Piper
- Baker Botts
- Finch Thornton
- Troutman
- Doyle Restrepo
- Coats Rose
- Probus Law Firm
- Kane Russell
- Katten Muchin
- Munsch Hardt
- Pashman Stein
- Buchalter LLP
- Rusty Hardin
- Reed Smith
- Gray Reed
- Andrews Myers
- Hodgson Russ
- Paul Hastings
- Porter Hedges
- Maynard Nexsen
- McGuireWoods
- ASK LLP
- Jones Walker LLP
- Christian Levine Law Group
- Harvest LLP
- Chapman & Cutler
- Law Office of Liz Freeman
- Miller Nash LLP
- Offit Kurman
- Tran Singh
- Franklin Soto Leeds
- Sidley Austin
- Christian Attar LLC
- Shook Hardy
- Haynes Boone
- K&L Gates
- Tucker Arensberg
- Quinn Emanuel
- Bressler Amery
- Ohashi & Horn
- Husch Blackwell
- Glenn Agre
- Ferguson Braswell
- Pillsbury Winthrop
- WilmerHale
- Warshaw Burstein
- Davis Graham
- Sheppard Mullin
- Cowles & Thompson
- Dykema
- Clark Hill
- Thompson Coburn
- Jackson Walker LLP
- Latham & Watkins
- Milbank LLP
Companies
- Cetera Financial Institutions
- LPL Financial
- Bank of America Corp.
- Moelis & Co.
- Pershing Group LLC
- Fortis Advisors LLC
- PCI Pharma Services
- The Charles Schwab Corp.
- Sorrento Therapeutics Inc.
- Interactive Brokers Group Inc.
- BMO Harris Bank NA
- BNY Mellon Investment Management
- FTI Consulting Inc.
- Raymond James Financial Inc.
- Apex Clearing Corporation
- Charles River Laboratories International Inc.
- Protiviti Inc.
- TR Capital Management LLC
- Precision for Medicine Holdings Inc.
- The Scripps Research Institute
- American Express Co.
- LPL Financial Holdings Inc.
- Mayo Foundation for Medical Education and Research
- Phillip Capital Inc.
- JPMorgan Chase & Co.
- Stretto Inc.
- Barclays PLC
- The Goldman Sachs Group Inc.
- Robert Half Inc.
- BMO Capital Markets Corp.
- New England Biolabs Inc.
- ABN AMRO Bank NV
- Emas Pharma Ltd.
- NantWorks LLC
- FMR LLC
- Wedbush Securities Inc.
- Kilroy Realty Corporation
- Prospect Medical Holdings Inc.
- Edward D. Jones & Co. LP
- Oracle Corp.
- The Bank of New York Mellon Corp.
- Morgan Stanley
- HSBC Holdings PLC
- UBS Group AG
Sectors & Industries:
-
March 17, 2023
Sorrento Shareholders Say They Need Committee In Ch. 11
Shareholders in pharmaceutical research company Sorrento Therapeutics have asked a Texas bankruptcy judge to order the appointment of a committee to represent them in Sorrento's Chapter 11 case and investigate potential claims against the company's management.
-
February 21, 2023
Sorrento Cleared For Ch. 11 Loan Over Nant Entity Objection
Bankrupt pharmaceutical research company Sorrento Therapeutics received interim approval Tuesday for a $75 million Chapter 11 loan after a Texas judge overruled objections from a litigation foe of the debtor's that argued the financing wouldn't add value to the estate.
-
February 13, 2023
Sorrento Therapeutics Hits Ch. 11 With Over $100M In Debt
California pharmaceutical research firm Sorrento Therapeutics Inc., a developer of cancer, COVID-19 and chronic pain treatments, filed for Chapter 11 protection in a Texas bankruptcy court Monday with about $135 million in debt.
- ← Previous
- 1
- 2
- 3
- 4
- Next →